VM BioPharma
Atlanta
Georgia
United States
Tel: 1-404-355-5434
About VM BioPharma
VM BioPharma is a US division of ViroMed Co., Ltd., an R&D focused biopharmaceutical company founded in 1996 and based in Seoul, Korea. ViroMed is developing new and innovative biopharmaceuticals for the treatment of currently untreatable diseases. The current development focus is on the proprietary plasmid DNA-based drug, VM202 in cardiovascular and neurological diseases at various clinical stages in US, Korea, and China.
YEAR FOUNDED:
1996
4 articles about VM BioPharma
-
VM BioPharma Announces Initiation of Hepatocyte Growth Factor to Improve Functioning in PAD, HI-PAD, Study of VM202 in Peripheral Artery Disease
12/1/2017
VM BioPharma today announced the launch of the HI-PAD study, a trial to investigate the effect of VM202, a DNA plasmid encoding HGF, on mobility and calf perfusion in older adults with PAD.
-
VM BioPharma Announces Generic Name "donaperminogene seltoplasmid" for Investigational Novel Gene Therapy, VM202
11/16/2017
The movement of donaperminogene seltoplasmid toward commercialization is further evidenced by the ongoing enrollment of two Phase III studies within the US.
-
VM BioPharma Announces First Patient Dosed In Phase III Study Of Gene Therapy Candidate VM202 For Non-Healing Diabetic Foot Ulcers
8/3/2017
-
VM BioPharma Announces Publication Of Phase I/II Clinical Data Of Novel Gene Therapy VM202 In Amyotrophic Lateral Sclerosis (ALS)
2/9/2017